Intraperitoneal (IP) port cytology after completion of primary therapy for advanced stage ovarian cancer: A novel approach to a "second look".

CONCLUSIONS: IP port cytology is predictive of recurrence and survival in patients with ovarian cancer. This inexpensive test may serve as an adjunct to imaging and tumor markers to determine disease status at the completion of treatment. Further study should investigate how this may impact management. PMID: 31160072 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31160072?dopt=Abstract

Source: Gynecologic Oncology - May 30, 2019 Category: Cancer & Oncology Authors: Grette K, Long B, Finan MA, Rocconi RP Tags: Gynecol Oncol Source Type: research